Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Greiner Website

John W. Greiner, Ph.D.

Selected Publications

1)  Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW.
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Oncotarget. 5: 1869-84, 2014.
2)  Takai S, Schlom J, Tucker J, Tsang KY, Greiner JW.
Inhibition of TGF-ß1 Signaling Promotes Central Memory T Cell Differentiation.
J. Immunol. 2013.
3)  Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, Greiner JW.
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Cancer Res. 64: 3668-78, 2004.
4)  Greiner JW, Zeytin H, Anver MR, Schlom J.
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Cancer Res. 62: 6944-51, 2002.
5)  Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW.
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Cancer Res. 61: 206-14, 2001.
6)  Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL.
Therapeutic cancer vaccines.
Adv. Cancer Res. 121: 67-124, 2014.
7)  Zaharoff DA, Heffernan M, Fallo J, Greiner JW.
Sarmento B, das Neves J, eds.
Preclinical and clinical use of chitosan and derivatives for biopharmaceuticals from preclinical research to the bedside (Chapter 27). In: Chitosan-based Systems for Biopharmaceuticals: Delivery, Targeting and Polymer Therapeutics.
New York: John Wiley & Sons; 2012. p. 525-541 [Book Chapter]
8)  Takai S, Sabzevari H, Farsaci B, Schlom J, Greiner JW.
Distinct effects of saracatinib on memory CD8+ T cell differentiation.
J. Immunol. 188: 4323-33, 2012.
9)  Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW.
In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines.
Biomaterials. 32: 926-32, 2011.
10)  Bonmassar L, Fossile E, Scoppola A, Graziani G, Prete SP, Formica V, Cappelletti D, De Vecchis L, Cardillo A, Concolino F, D'Atri S, Balduzzi A, Torino F, Caporaso P, Greiner JW, Bonmassar E, Roselli M, Aquino A.
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies.
Anticancer Res. 30: 4721-30, 2010.
11)  Zaharoff DA, Hance KW, Rogers CJ, Schlom J, Greiner JW.
Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12.
Journal of immunotherapy (Hagerstown, Md. : 1997). 33: 697-705, 2010.
12)  Zaharoff DA, Hoffman BS, Hooper HB, Benjamin Jr CJ, Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW.
Intravesical immunotherapy of superficial bladder cancer with chitosan/IL-12.
Cancer Res. 69: 6192-9, 2009.
13)  Hance KW, Rogers CJ, Zaharoff DA, Canter D, Schlom J, Greiner JW.
The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
Clin. Cancer Res. 15: 2387-96, 2009.
14)  Rogers CJ, Berrigan D, Zaharoff DA, Hance KW, Patel AC, Perkins SN, Schlom J, Greiner JW, Hursting SD.
Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.
J. Nutr. 138: 115-22, 2008.
15)  Rogers CJ, Zaharoff DA, Hance KW, Perkins SN, Hursting SD, Schlom J, Greiner JW.
Exercise enhances vaccine-induced antigen-specific T cell responses.
Vaccine. 2008.
16)  Rogers CJ, Colbert LH, Greiner JW, Perkins SN, Hursting SD.
Physical activity and cancer prevention : pathways and targets for intervention.
Sports medicine (Auckland, N.Z.). 38: 271-96, 2008.
17)  Zeytin H, Reali E, Zaharoff DA, Rogers CJ, Schlom J, Greiner JW.
Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.
J. Interferon Cytokine Res. 28: 73-87, 2008.
18)  Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, Hodge JW.
Vaccination with a recombinant saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.
Clin. Cancer Res. 14: 4316-25, 2008.
19)  Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW.
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.
Vaccine. 25: 2085-94, 2007.
20)  Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW.
Chitosan solution enhances the immunoadjuvant properties of GM-CSF.
Vaccine. 25: 8673-86, 2007.
21)  Hance KW, Rogers CJ, Hursting SD, Greiner JW.
Combination of physical activity, nutrition, or other metabolic factors and vaccine response.
Front. Biosci. 12: 4997-5029, 2007.
22)  Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J.
Costimulatory molecules as adjuvants for immunotherapy.
Front. Biosci. 11: 788-803, 2006.
23)  Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.
TRICOM vector based cancer vaccines.
Curr. Pharm. Des. 12: 351-61, 2006.
24)  Reali E, Canter D, Zeytin H, Schlom J, Greiner JW.
Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.
Vaccine. 23: 2909-21, 2005.
25)  Hance KW, Zeytin HE, Greiner JW.
Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines.
Mutat. Res. 576: 132-54, 2005.
26)  Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW.
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Developments in biologicals. 116: 27-47, 2004.
27)  Palena C, Arlen P, Zeytin H, Greiner JW, Schlom J, Tsang KY.
Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
Cytokine. 24: 128-42, 2003.
28)  Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C.
Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.
Cancer Res. 62: 5049-57, 2002.
29)  Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J, Greiner JW.
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Cancer Res. 62: 5058-64, 2002.
30)  Prete SP, Cappelletti D, Baier S, Nasuti P, Guadagni F, De Vecchis L, Greiner JW, Bonmassar E, Graziani G, Aquino A.
Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine.
Int. Immunopharmacol. 2: 641-51, 2002.
31)  Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.
Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Cancer Res. 61: 2523-32, 2001.
32)  Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, Schlom J, Siccardi AG.
IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines.
Cancer Res. 61: 5517-22, 2001.
33)  Kass E, Parker J, Schlom J, Greiner JW.
Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes.
Cytokine. 12: 960-71, 2000.
34)  Cappelletti D, Cardillo A, Bonanno E, Prete SP, Cucchiara G, Turriziani M, Greiner JW, Cottarelli A, Breda E, Aquino A, Bonmassar E, De Vecchis L.
Drug-induced modulation of carcinoembryonic antigen (CEA) expression in neoplastic cells from a patient with rectal cancer.
J. Exp. Clin. Cancer Res. 19: 467-9, 2000.
35)  Aquino A, Prete SP, Baier S, Cappelletti D, Greiner JW, De Vecchis L, Graziani G, Bonmassar E.
Staurosporine increases carcinoembryonic antigen expression in a human colon cancer cell line.
Journal of chemotherapy (Florence, Italy). 12: 167-72, 2000.
36)  Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW.
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Cancer Res. 59: 676-83, 1999.
37)  Popescu NC, Greiner JW.
Recurrent alterations of the short arm of chromosome 3 define a tumor suppressor region in rat mammary tumor cells.
Carcinogenesis. 20: 2033-6, 1999.
38)  Aquino A, Prete SP, Greiner JW, Giuliani A, Graziani G, Turriziani M, De Filippi R, Masci G, Bonmassar E, De Vecchis L.
Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.
Clin. Cancer Res. 4: 2473-81, 1998.
39)  Roselli M, Buonomo O, Piazza A, Guadagni F, Vecchione A, Brunetti E, Cipriani C, Amadei G, Nieroda C, Greiner JW, Casciani CU.
Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation.
Seminars in surgical oncology. 15: 254-62, 1998.
40)  Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, Rieger PT, LeBherz D, South M, Greiner JW, Schlom J, Podoloff DA, Murray JL.
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Clin. Cancer Res. 3: 1547-55, 1997.
41)  McLaughlin JP, Abrams S, Kantor J, Dobrzanski MJ, Greenbaum J, Schlom J, Greiner JW.
Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
J. Immunother. 20: 449-59, 1997.
42)  Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, D'Alessandro R, Fracasso PL, Casale V, Vecchione A, Casciani CU, Greiner JW, Schlom J.
Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation.
Int. J. Cancer. 72: 949-54, 1997.
43)  Spila A, Roselli M, Cosimelli M, Ferroni P, Cavaliere F, Arcuri R, Tedesco M, Carlini S, D'Alessandro R, Perri P, Casciani CU, Greiner JW, Schlom J, Guadagni F.
Clinical utility of CA 72-4 serum marker in the staging and immediate post-surgical management of gastric cancer patients.
Anticancer Res. 16: 2241-7, 1996.
44)  Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito MR, Casale V, Pericoli MN, Vecchione A, Casciani CU, Greiner JW, Schlom J.
Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay.
Cancer Res. 56: 5293-8, 1996.
45)  Prete SP, Aquino A, Masci G, Orlando L, Giuliani A, De Santis S, De Vecchis L, De Filippi R, Greiner JW, Bonmassar E, Graziani G.
Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil.
J. Pharmacol. Exp. Ther. 279: 1574-81, 1996.
46)  McLaughlin JP, Schlom J, Kantor JA, Greiner JW.
Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
Cancer Res. 56: 2361-7, 1996.
47)  Greiner JW, Guadagni F, Roselli M, Nieroda CA.
Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine.
Anticancer Res. 16: 2129-33, 1996.
48)  Roselli M, Guadagni F, Buonomo O, Belardi A, Vittorini V, Mariani-Costantini R, Greiner JW, Casciani CU, Schlom J.
Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen.
J. Clin. Oncol. 14: 2031-42, 1996.
49)  Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Arcuri R, Carlini S, Mariotti S, Gandolfo GM, Casciani CU, Greiner JW, Schlom J.
TAG-72 expression and its role in the biological evaluation of human colorectal cancer.
Anticancer Res. 16: 2141-8, 1996.
50)  Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW.
CA 72-4 serum marker--a new tool in the management of carcinoma patients.
Cancer Invest. 13: 227-38, 1995.
51)  Nieroda CA, Milenic DE, Carrasquillo JA, Scholm J, Greiner JW.
Improved tumor radioimmunodetection using a single-chain Fv and gamma-interferon: potential clinical applications for radioimmunoguided surgery and gamma scanning.
Cancer Res. 55: 2858-65, 1995.
52)  Dansky-Ullmann C, Salgaller M, Adams S, Schlom J, Greiner JW.
Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta.
Cytokine. 7: 118-29, 1995.
53)  Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Arcuri R, Abbolito MR, Greiner JW, Schlom J.
Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, Part I.
Dis. Colon Rectum. 37: S16-23, 1994.
54)  De Filippi R, Prete SP, Giuliani A, Silvi E, Yamaue H, Nieroda CA, Greiner JW, De Vecchis L, Bonmassar E.
Differential effects of recombinant interferon-alpha and 5-fluorouracil against colon cancer cells or against peripheral blood mononuclear cells.
Anticancer Res. 14: 1767-73, 1994.
55)  Guadagni F, Marth C, Zeimet AG, Ferroni P, Spila A, Abbolito R, Roselli M, Greiner JW, Schlom J.
Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases.
Am. J. Obstet. Gynecol. 171: 1183-91, 1994.
56)  Greiner JW, Guadagni F, Roselli M, Ullmann CD, Nieroda C, Schlom J.
Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma.
Dis. Colon Rectum. 37: S100-5, 1994.
57)  Guadagni F, Roselli M, Schlom J, Greiner JW.
In vitro and in vivo regulation of human tumor antigen expression by human recombinant interferons: a review.
Int. J. Biol. Markers. 9: 53-60, 1994.
58)  Shimada S, Ogawa M, Takahashi M, Schlom J, Greiner JW.
Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon.
Cancer Res. 54: 3831-6, 1994.
59)  Tsang KY, Kashmiri SV, De Filippi R, Qi CF, Calvo B, Shu L, Nieroda CA, Greiner JW, Schlom J.
A human T cell line engineered to secrete chimeric monoclonal antibody.
J. Immunother. 13: 143-52, 1993.
60)  Guadagni F, Roselli M, Nieroda C, Dansky-Ullmann G, Schlom J, Greiner JW.
Biological response modifiers as adjuvants in monoclonal antibody-based treatment (review).
In Vivo. 7: 591-9, 1993.
61)  Shimada S, Ogawa M, Schlom J, Greiner JW.
Comparison of the interferon-gamma-mediated regulation of tumor-associated antigens expressed by human gastric carcinoma cells.
In Vivo. 7: 1-8, 1993.
62)  Greiner JW, Ullmann CD, Nieroda C, Qi CF, Eggensperger D, Shimada S, Steinberg SM, Schlom J.
Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
Cancer Res. 53: 600-8, 1993.
63)  Guadagni F, Roselli M, Cosimelli M, Mannella E, Tedesco M, Cavaliere F, Grassi A, Abbolito MR, Greiner JW, Schlom J.
TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer.
Cancer. 72: 2098-106, 1993.
64)  Tsang KY, Kashmiri SV, Qi CF, Nieroda C, Calvo B, De Filippi R, Greiner JW, Primus FJ, Schlom J.
Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.
Immunol. Lett. 36: 179-85, 1993.
65)  Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, Carlini M, Santoro E, Cavaliere R, Greiner JW.
CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma.
Cancer Res. 52: 1222-7, 1992.
66)  Ullmann CD, Schlom J, Greiner JW.
Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells.
J. Immunother. 12: 231-41, 1992.
67)  Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden EC, Simpson JF, Molinolo A, Schlom J.
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.
J. Clin. Oncol. 10: 735-46, 1992.
68)  Greiner JW, Smalley RV, Borden EC, Martin EW, Guadagni F, Roselli M, Schlom J.
Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas.
Journal of surgical oncology. Supplement. 2: 9-13, 1991.
69)  Guadagni F, Tortora G, Roselli M, Clair T, Cho-Chung YS, Schlom J, Greiner JW.
Carcinoembryonic antigen regulation in human colorectal tumor cells by a site-selective cyclic AMP analogue: a comparison with interferon-gamma.
Int. J. Cancer. 48: 413-22, 1991.
70)  Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Tedesco M, Grassi A, Casale V, Cavaliere F, Greiner JW.
Clinical evaluation of serum tumor-associated glycoprotein-72 as a novel tumor marker for colorectal cancer patients.
Journal of surgical oncology. Supplement. 2: 16-20, 1991.
71)  Guadagni F, Roselli M, Ferroni P, Amato T, Colcher D, Greiner JW, Schlom J.
Clinical evaluation of the new tumor marker TAG-72.
Anticancer Res. 11: 1389-94, 1991.
72)  Greiner JW, Guadagni F, Goldstein D, Borden EC, Ritts RE, Witt P, LoBuglio AF, Saleh MN, Schlom J.
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.
Cancer Res. 51: 4155-63, 1991.
73)  Shimada S, Ogawa M, Schlom J, Greiner JW.
Identification of a novel tumor-associated Mr 110,000 gene product in human gastric carcinoma cells that is immunologically related to carcinoembryonic antigen.
Cancer Res. 51: 5694-703, 1991.
74)  Guadagni F, Schlom J, Greiner JW.
In vitro and in vivo regulation of tumor antigen expression by human recombinant interferons.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology. 18: 409-12, 1991.
75)  Roselli M, Casciani CU, Guadagni F, Buonomo O, Iorio B, Diodati A, Vittorini V, Greiner JW, Colcher D, Schlom J.
Monoclonal antibodies in the management of carcinoma patients.
Medical oncology and tumor pharmacotherapy. 8: 223-8, 1991.
76)  Schlom J, Milenic DE, Roselli M, Colcher D, Bird R, Johnson S, Hardman KD, Guadagni F, Greiner JW.
New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology. 18: 425-35, 1991.
77)  Guadagni F, Roselli M, Schlom J, Greiner JW.
Regulation of human tumor antigen expression by biological response modifiers (BRMs).
Ann. Ist. Super. Sanita. 27: 71-8, 1991.
78)  Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Perri P, Abbolito MR, Cavaliere R, Colcher D, Greiner JW.
Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study.
Cancer. 68: 2443-50, 1991.
79)  Greiner JW, Guadagni F, Hand PH, Pestka S, Noguchi P, Fisher PB, Schlom J.
Augmentation of tumor antigen expression by recombinant human interferons: enhanced targeting of monoclonal antibodies to carcinomas.
Cancer Treat. Res. 51: 413-32, 1990.
80)  Ferroni P, Szpak C, Greiner JW, Simpson JF, Guadagni F, Johnston WW, Colcher D.
CA 72-4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers.
Int. J. Cancer. 46: 445-51, 1990.
81)  Guadagni F, Roselli M, Amato T, Abbolito MR, Cosimelli M, Mannella E, Greiner JW, Schlom J.
Evaluation of TAG-72 and CEA tumor markers in sera of patients with gastrointestinal adenocarcinomas.
J. Nucl. Med. Allied Sci. 34: 293-6, 1990.
82)  Schlom J, Hand PH, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, Larson SM, Raubitschek A.
Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting.
Cancer Res. 50: 820s-827s, 1990.
83)  Guadagni F, Witt PL, Robbins PF, Schlom J, Greiner JW.
Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma.
Cancer Res. 50: 6248-55, 1990.
84)  Muraro R, Nuti M, Natali PG, Bigotti A, Simpson JF, Primus FJ, Colcher D, Greiner JW, Schlom J.
A monoclonal antibody (D612) with selective reactivity for malignant and normal gastro-intestinal epithelium.
Int. J. Cancer. 43: 598-607, 1989.
85)  Leon JA, Mesa-Tejada R, Gutierrez MC, Estabrook A, Greiner JW, Schlom J, Fisher PB.
Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.
Anticancer Res. 9: 1639-47, 1989.
86)  Guadagni F, Schlom J, Johnston WW, Szpak CA, Goldstein D, Smalley R, Simpson JF, Borden EC, Pestka S, Greiner JW.
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.
J. Natl. Cancer Inst. 81: 502-12, 1989.
87)  Kuroki M, Greiner JW, Simpson JF, Primus FJ, Guadagni F, Schlom J.
Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies.
Int. J. Cancer. 44: 208-18, 1989.
88)  Tran R, Kashmiri SV, Kantor J, Greiner JW, Pestka S, Shively JE, Schlom J.
Correlation of DNA hypomethylation with expression of carcinoembryonic antigen in human colon carcinoma cells.
Cancer Res. 48: 5674-9, 1988.
89)  Tran R, Hand PH, Greiner JW, Pestka S, Schlom J.
Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons.
J. Interferon Res. 8: 75-88, 1988.
90)  Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson JF, Molinolo A, Noguchi P.
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
Cancer Res. 48: 4588-96, 1988.
91)  Guadagni F, Schlom J, Pothen S, Pestka S, Greiner JW.
Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon.
Cancer Immunol. Immunother. 26: 222-30, 1988.
92)  Greiner JW, Hand PH, Colcher D, Weeks M, Thor A, Noguchi P, Pestka S, Schlom J.
Modulation of human tumor antigen expression.
J. Lab. Clin. Med. 109: 244-61, 1987.
93)  Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB, Schlom J.
Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo.
Science. 235: 895-8, 1987.
94)  Lundy J, Greiner JW, Colcher D.
Development of a metastatic human colon cancer xenograft model in the nude mouse.
Journal of surgical oncology. 31: 260-7, 1986.
95)  Greiner JW, Fisher PB, Pestka S, Schlom J.
Differential effects of recombinant human leukocyte interferons on cell surface antigen expression.
Cancer Res. 46: 4984-90, 1986.
96)  Fisher PB, Grant S, Greiner JW, Schlom J.
Measurement of the effect of interferons on the proliferative capacity and cloning efficiency of normal and leukemic human myeloid progenitor cells in culture.
Meth. Enzymol. 119: 629-34, 1986.
97)  Greiner JW.
Modulation of antigen expression in human tumor cell populations.
Cancer Invest. 4: 239-56, 1986.
98)  Greiner JW, Horan Hand P, Wunderlich D, Colcher D.
Radioimmunoassay for detection of changes in cell surface tumor antigen expression induced by interferon.
Meth. Enzymol. 119: 682-8, 1986.
99)  Lundy J, Mornex F, Keenan AM, Greiner JW, Colcher D.
Radioimmunodetection of human colon carcinoma xenografts in visceral organs of congenitally athymic mice.
Cancer. 57: 503-9, 1986.
100)  Greiner JW.
Recombinant human leukocyte interferon induces alterations in the antigen phenotype of human breast carcinoma cells.
Anticancer Res. 6: 653-8, 1986.
101)  Greiner JW, Tobi M, Fisher PB, Langer JA, Pestka S.
Differential responsiveness of cloned mammary carcinoma cell populations to the human recombinant leukocyte interferon enhancement of tumor antigen expression.
Int. J. Cancer. 36: 159-66, 1985.
102)  Greiner JW, Schlom J, Pestka S, Langer JA, Giacomini P, Kusama M, Ferrone S, Fisher PB.
Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons.
Pharmacol. Ther. 31: 209-36, 1985.
103)  Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S, Schlom J.
Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.
Cancer Res. 44: 3208-14, 1984.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.